Zbtb44 belongs to the ZBTB family of transcription factors, a group of proteins defined by an array of zinc fingers that grip specific DNA sequences and a BTB protein-interaction domain that recruits regulatory machinery. Family members such as PLZF, Bcl-6, ThPOK and Miz-1 have well-documented roles in lymphocyte development and function, but Zbtb44 had remained largely uncharacterized in the immune system. Prior hints of its importance came from cancer genetics, where a ZBTB44-FLT3 fusion gene was reported in a patient with a myeloproliferative neoplasm. The new work is among the first to assign the protein a clear physiological job: keeping the inflammatory output of T cells within safe limits in the intestinal tract.

The researchers generated mice in which the Zbtb44 gene was deleted and observed that these animals, as they aged, developed spontaneous inflammation of the colon severe enough to cause weight loss and rectal prolapse. Importantly, younger Zbtb44-deficient mice showed normal T cell development in the thymus, spleen and lymph nodes, indicating that the protein is not required to build the immune system but rather to discipline it. Heterozygous animals carrying a single functional copy of the gene did not develop spontaneous colitis, and co-housing experiments showed that the disease could not be transmitted to wild-type cage mates through the microbiota. Sequencing of fecal 16S ribosomal RNA revealed no dramatic shifts in bacterial community composition that could explain the phenotype, pointing instead to an intrinsic defect within the immune compartment.

That intrinsic defect centered on a single, familiar culprit: interferon-gamma. T cells lacking Zbtb44 produced markedly elevated amounts of this potent pro-inflammatory cytokine, a signaling molecule that is strongly associated with human inflammatory bowel disease. Interferon-gamma is classically the signature product of Th1 lineage T cells, whose differentiation is directed by the transcription factor T-bet, and it drives epithelial barrier dysfunction, chemokine production and macrophage activation in the intestinal wall. Using mass cytometry and flow cytometry, the team documented excess interferon-gamma production across CD4-positive and CD8-positive T cell populations in the knockout mice, including after infection with lymphocytic choriomeningitis virus, showing that the derepression is not confined to a single activation context.

To determine whether the excess interferon-gamma was merely a byproduct or the actual driver of disease, the investigators turned to loss-of-function and transfer experiments. When interferon-gamma was neutralized or absent, the severe colitis in Zbtb44-deficient mice was substantially ameliorated, in both chemically induced models and in adoptive transfer settings where naive T cells are introduced into lymphocyte-deficient recipients. Conversely, the colitis phenotype followed the T cells: mice lacking T cells altogether did not develop the spontaneous disease, and the pathology reconstituted when Zbtb44-deficient T cells were transferred in. Together these results establish a causal chain in which Zbtb44 loss unleashes T cell interferon-gamma, and unrestrained interferon-gamma in turn destroys the colonic epithelium.

The mechanistic heart of the paper lies in how Zbtb44 finds and silences the interferon-gamma gene, known as Ifng. Chromatin profiling using CUT&RUN, a technique that maps protein-DNA interactions with base-pair precision, revealed that Zbtb44 binds directly to the Ifng promoter and to regulatory enhancer elements within the locus. RNA sequencing confirmed that in the absence of Zbtb44, transcription from these sites increases, and CRISPR-based interference targeting the Zbtb44 binding sites in the Ifng locus reproduced the elevated cytokine expression even in otherwise normal cells. The data place Zbtb44 squarely in the small but growing category of dedicated silencers of the interferon-gamma gene, alongside elements such as the distal CNS-28 silencer described in earlier work, and highlight how the architecture of repression at this locus safeguards tissue homeostasis.

Perhaps the most surprising discovery concerns how Zbtb44 is recruited to its target. The team found that Zbtb44 undergoes SUMOylation, a post-translational modification in which a small ubiquitin-like modifier peptide is covalently attached to the protein. This modification enables Zbtb44 to engage a conserved SUMO-interacting motif within T-bet, the master transcription factor of Th1 cells. In effect, the repressor and the activator physically partner at the interferon-gamma promoter and enhancer, with Zbtb44 riding on T-bet to dampen the very program that T-bet initiates. When SUMOylation was disrupted, the interaction collapsed, Zbtb44 could no longer restrain the locus, and interferon-gamma production soared. This SUMO-dependent repressor-activator pairing offers an elegant explanation for how chronic cytokine output is kept in check even in cells committed to an inflammatory fate.

The study also connected the mouse findings to human disease. Single-cell RNA sequencing analyses of colon biopsy samples from patients with ulcerative colitis showed Zbtb44 expression in CD8-positive T cells and natural killer cell populations within inflamed tissue, suggesting that the regulatory circuit the researchers dissected in mice operates in the human gut as well. Given that interferon-gamma contributes to epithelial barrier breakdown and to the IL-23-driven inflammatory axis implicated in Crohn’s disease, a transcriptional brake on this cytokine represents an attractive node for intervention. Current cytokine-targeting strategies in inflammatory bowel disease, including antibodies against tumor necrosis factor, interleukin-12/23 and integrins, leave many patients undertreated, and the identification of intracellular repressors opens the possibility of small-molecule approaches that modulate SUMOylation or protein-protein interactions rather than blocking cytokines extracellularly.

Caveats remain before such translational ambitions can be realized. The work was performed predominantly in mice, and the precise contribution of Zbtb44 variants to human inflammatory bowel disease susceptibility has not been established through genetic association studies. SUMOylation touches hundreds of cellular substrates, so systemically manipulating the pathway carries broad risks, and any therapeutic strategy would need to achieve specificity for the T cell compartment. Nevertheless, the study delivers a conceptually satisfying message: the immune system depends not only on transcriptional activators that launch inflammatory programs but equally on repressors that keep those programs from running amok. With Zbtb44 now identified as a key SUMO-dependent silencer of interferon-gamma, researchers have a new molecular handle on one of the most consequential cytokines in intestinal immunity, and a fresh answer to the long-standing question of how the gut tolerates its teeming microbial residents without succumbing to self-destruction.

Subject of Research: Transcriptional repression of T cell interferon-gamma by Zbtb44 in colonic inflammation

Article Title: Zbtb44-mediated transcriptional repression critically regulates colonic inflammation

Article References: Zbtb44-mediated transcriptional repression critically regulates colonic inflammation. (n.d.). https://doi.org/10.1038/s41590-026-02675-4

Image Credits: AI Generated

DOI: 10.1038/s41590-026-02675-4

Keywords: Zbtb44, transcription factor, colitis, interferon-gamma, T-bet, SUMOylation, T cells, inflammatory bowel disease, Nature Immunology, immune regulation, mucosal immunology, transcriptional repression